Sutro Biopharma Valuation Multiples

Sutro Biopharma Overview

About Sutro Biopharma

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Founded

2003

HQ

Employees

338

Website

sutrobio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $85M

EBITDA: ($138M)

EV

$190M

Valuation Multiples

Multiples.vc

Start free trial

Sutro Biopharma Financials

Sutro Biopharma reported last 12-month revenue of $85M and negative EBITDA of ($138M).

In the same LTM period, Sutro Biopharma generated $85M in gross profit, ($138M) in EBITDA losses, and had net loss of ($157M).

Sutro Biopharma P&L

In the most recent fiscal year, Sutro Biopharma reported revenue of $62M and EBITDA of ($187M).

Sutro Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Sutro Biopharma Stock Performance

Sutro Biopharma has current market cap of $340M, and enterprise value of $190M.

Sutro Biopharma's stock price is $20.77.

Sutro Biopharma Valuation Multiples

Sutro Biopharma trades at 2.2x EV/Revenue multiple, and (1.4x) EV/EBITDA.

Sutro Biopharma Financial Valuation Multiples

As of March 21, 2026, Sutro Biopharma has market cap of $340M and EV of $190M.

Equity research analysts estimate Sutro Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Sutro Biopharma has a P/E ratio of (2.2x).

Sutro Biopharma Margins & Growth Rates

Sutro Biopharma's revenue in the last 12 month declined by (56%).

Sutro Biopharma's revenue per employee in the last FY averaged $0.3M.

Sutro Biopharma's rule of 40 is (218%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Sutro Biopharma's rule of X is (301%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Sutro Biopharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Sutro Biopharma M&A Activity

Sutro Biopharma acquired XXX companies to date.

Last acquisition by Sutro Biopharma was on XXXXXXXX, XXXXX. Sutro Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Sutro Biopharma Investment Activity

Sutro Biopharma invested in XXX companies to date.

Sutro Biopharma made its latest investment on XXXXXXXX, XXXXX. Sutro Biopharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).